Recruiting

Pilot Observational Study of an Integrative Cure Stay Program

This pilot observational study evaluates the feasibility and acceptability of conducting a prospective study alongside the individualized integrative oncology cure stay program "Via Shalva" for breast and gynecological cancer survivors. The study further explores preliminary changes in patient-reported outcomes, physiological measures, and biological markers before and after the retreat and compared with a matched control group.

I'm interested View official listing
ClinicalTrials.gov IDNCT07398079
PhaseNot Applicable
Enrollment30
SponsorUniversity Hospital, Basel, Switzerland
Age18 Years and older
SexFEMALE
I'm interested View official listing

Conditions studied

Breast Cancer, Gynecologic Cancer

About this study

This pilot observational study evaluates the feasibility and acceptability of conducting a prospective study alongside the individualized integrative oncology cure stay program "Via Shalva" for breast and gynecological cancer survivors. The study further explores preliminary changes in patient-reported outcomes, physiological measures, and biological markers before and after the retreat and compared with a matched control group.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Breast and gynecological cancer (including but not limited to ovarian, endometrial, cervical, vulvar and vaginal cancer) survivors, including recurrent disease * Completed primary treatment (operation +/- radiation +/- chemotherapy) * Age ≥ 18 years * Ongoing or planned maintenance treatment scheduled for \> 3 months during study period is allowed (e.g. antihormonal therapy, Anti-Her2-antibodies, CDK4/6-inhibitors, Anti-VEGF-inhibitor, PARP-inhibitor, immune-checkpoint inhibitors etc.) * Signed informed consent for participation of the trials * Presence of a stoma is allowed * Prior cancer is allowed * Prior treatment - including chemotherapy - for a prior malignant tumor (including breast or gynecological cancer) is allowed * Concomitant participation in an experimental therapeutic drug trial is allowed * Use of other complementary methods (including mistletoe) is allowed * Pregnancy is allowed. Exclusion Criteria: * Language or cognitive deficits (including impaired consciousness) that are incompatible with the participation in the study * Severe physical or psychiatric comorbidity that prevents a patient from participating in the study * Patients incapable of giving consent

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-12.